We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.60+0.1%12:44 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen6/29/2005 10:00:39 AM
   of 347
GenoMed CEO Testifies Before Missouri Medicaid Reform Commission

Contact: David Moskowitz MD FACP GenoMed, Inc. tel. 314-983-9933

ST. LOUIS--(June 29, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to testify today, the first day of public testimony, before the Missouri Medicaid Reform Commission. The Medicaid Reform Commission is a joint committee of the Missouri House and Senate empanelled to study ways to rein in rising healthcare costs for the Missouri state Medicaid program.

As a first attempt, the Missouri Legislature cut 65,000 patients from the state Medicaid program this spring. These patients lose coverage on July 1st, i.e. this Friday. Since oxygen tanks are among the items no longer covered, many patients will soon die.

Said Dr. Moskowitz, "I'm honored to represent GenoMed and the promise of genomics-based medicine at the very first session of public testimony before the Missouri Medicaid Reform Commission. I'm happy to describe the dramatic cost-savings that Next Generation Disease Management can yield, as I did last week for the AFL-CIO Healthcare Taskforce in Washington, DC. My earnest hope is that Missouri legislators will consider adopting our protocols and stop the disenrollments before a single patient has died."

Added Dr. Moskowitz, "The Missouri Legislature is wrestling with the most critical domestic issue of our time. It is literally a life and death issue for tens of millions of Americans. It seems to me profoundly un-American, on the eve of our nation's birthday, to have people die simply because Medicaid is still paying retail for drugs. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."

About GenoMed

GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. DM (Disease Management) is the only healthcare player whose business model is to profit by lowering healthcare costs. A St. Louis Business Journal article ( first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext